These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 31815956)

  • 1. Prevalence of drug-drug interaction in atrial fibrillation patients based on a large claims data.
    Momo K; Kobayashi H; Sugiura Y; Yasu T; Koinuma M; Kuroda SI
    PLoS One; 2019; 14(12):e0225297. PubMed ID: 31815956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Major Bleeding Among Working-Age Adults with Atrial Fibrillation: Evaluating the Effects of Potential Drug-drug Interactions and Switching from Warfarin to Non-vitamin K Oral Anticoagulants.
    Feng X; Sambamoorthi U; Innes K; Castelli G; LeMasters T; Xiong L; Williams MU; Tan X
    Cardiovasc Drugs Ther; 2018 Dec; 32(6):591-600. PubMed ID: 30315487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of hemorrhage and treatment costs associated with warfarin drug interactions in patients with atrial fibrillation.
    Suh DC; Nelson WW; Choi JC; Choi I
    Clin Ther; 2012 Jul; 34(7):1569-82. PubMed ID: 22717419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare Utilization and Expenditures in Working-Age Adults with Atrial Fibrillation: The Effect of Switching from Warfarin to Non-Vitamin K Oral Anticoagulants.
    Feng X; Sambamoorthi U; Innes K; LeMasters T; Castelli G; Dwibedi N; Tan X
    Am J Cardiovasc Drugs; 2018 Dec; 18(6):513-520. PubMed ID: 30144015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleeding Risk of Warfarin and Direct Oral Anticoagulants in Younger Population: A Historical Cohort Study Using a Japanese Claims Database.
    Yokoyama S; Tanaka Y; Nakagita K; Hosomi K; Takada M
    Int J Med Sci; 2018; 15(14):1686-1693. PubMed ID: 30588192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
    Hellwig T; Gulseth M
    Ann Pharmacother; 2013 Nov; 47(11):1478-87. PubMed ID: 24259602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
    Agarwal S; Bennett D; Smith DJ
    Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The increased risk of bleeding due to drug-drug interactions in patients administered direct oral anticoagulants.
    Lee JY; Oh IY; Lee JH; Kim SY; Kwon SS; Yang HJ; Kim YK; Bang SM
    Thromb Res; 2020 Nov; 195():243-249. PubMed ID: 32823239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of bleeding with dabigatran in atrial fibrillation.
    Hernandez I; Baik SH; Piñera A; Zhang Y
    JAMA Intern Med; 2015 Jan; 175(1):18-24. PubMed ID: 25365537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
    Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
    Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying high risk medications causing potential drug-drug interactions in outpatients: A prescription database study based on an online surveillance system.
    Toivo TM; Mikkola JA; Laine K; Airaksinen M
    Res Social Adm Pharm; 2016; 12(4):559-68. PubMed ID: 26459026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting.
    McCormick D; Gurwitz JH; Goldberg RJ; Becker R; Tate JP; Elwell A; Radford MJ
    Arch Intern Med; 2001 Nov; 161(20):2458-63. PubMed ID: 11700158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation.
    Howard PA; Ellerbeck EF; Engelman KK; Patterson KL
    Pharmacoepidemiol Drug Saf; 2002; 11(7):569-76. PubMed ID: 12462133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major bleeding risk associated with warfarin and co-medications in the elderly population.
    Vitry AI; Roughead EE; Ramsay EN; Preiss AK; Ryan P; Gilbert AL; Caughey GE; Shakib S; Esterman A; Zhang Y; McDermott RA
    Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1057-63. PubMed ID: 22039594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term stroke and bleeding risk in patients with atrial fibrillation treated with oral anticoagulants in contemporary practice: Providing evidence for shared decision-making.
    Noseworthy PA; Yao X; Gersh BJ; Hargraves I; Shah ND; Montori VM
    Int J Cardiol; 2017 Oct; 245():174-177. PubMed ID: 28733071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Warfarin exposure and the risk of thromboembolic and major bleeding events among medicaid patients with atrial fibrillation.
    Boulanger L; Hauch O; Friedman M; Foster T; Dixon D; Wygant G; Menzin J
    Ann Pharmacother; 2006 Jun; 40(6):1024-9. PubMed ID: 16735649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
    JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin.
    Gasse C; Hollowell J; Meier CR; Haefeli WE
    Thromb Haemost; 2005 Sep; 94(3):537-43. PubMed ID: 16268469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy.
    Fosbol EL; Wang TY; Li S; Piccini J; Lopes RD; Mills RM; Klaskala W; Thomas L; Roe MT; Peterson ED
    Am Heart J; 2013 Nov; 166(5):864-70. PubMed ID: 24176442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.
    Kohsaka S; Murata T; Izumi N; Katada J; Wang F; Terayama Y
    Curr Med Res Opin; 2017 Nov; 33(11):1955-1963. PubMed ID: 28857611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.